Bectumomab is a monoclonal antibody that was developed for use in the treatment of certain types of cancer, particularly non-Hodgkin lymphoma. It specifically targets the CD19 antigen, which is commonly expressed on the surface of B-cell lymphoid malignancies. By binding to CD19, Bectumomab may help to direct the immune system's response against cancer cells, potentially leading to their destruction.
Articles by others on the same topic
There are currently no matching articles.